STADA Arzneimittel — 9M 2016 Earnings Presentation
16 slides from STADA Arzneimittel's earnings presentation, Nov 10, 2016
Slide 1: Analyst Conference Call 9M/2016 Results
ANALYST CONFERENCE CALL 9M/2016 RESULTS November 10, 2016
Slide 2: Q3: A High Performance Despite Challenging Environment and a Strong Prior-Year Quarter
Q3: A HIGH PERFORMANCE DESPITE CHALLENGING ENVIRONMENT AND A STRONG PRIOR-YEAR QUARTER Generics Cashflow o Ongoing strong sales momentum: o Sequential improvement in Operating Cashflow Russia with continued double-digit sales o Significant increase in Free Cashflow growth / Belgium recovering o Segm
Slide 3: Financial Overview
FINANCIAL OVERVIEW Group Results €m Q3/2016 Q3/2015 Δ 9M/2016 9M/2015 Δ Sales 507 508 0% 1,542 1,534 1% Sales (adj.)1 507 504 1% 1,568 1,522 3% EBITDA 88 100 -11% 289 281 3% EBITDA (adj.)2 98 105 -6% 301 294 2% Financial result -13 -16 17% -38 -50 25% Income taxes -3 -14 80% -28 -34 20% Net Income 1
Slide 4: Generics
GENERICS Q3 Segment Results €m Q3/2016 Q3/2015 Δ 9M/2016 9M/2015 Δ Sales 305 292 4% 932 928 0% Sales (adj.)1 304 290 5% 944 922 2% EBITDA (adj.)2 64 49 30% 194 161 20% Margin (adj.)2 21.0% 16.8% 20.8% 17.3% 1) Adjusted for currency and portfolio effects. 2) Adjusted for special items STADA Analyst C
Slide 5: Generics: Q3 Segment Results and Sales by Country
GENERICS Q3 Segment Results Sales by country Q3/2016 in €m • Germany: Following expired tenders more selected approach in renewals with stronger focus on profitability 77 73 Germany (9%) (-12%) • Russia: Ongoing sales momentum despite Italy challenging environment Generics Spain 305 €m Russia • Belg
Slide 6: Branded Products
BRANDED PRODUCTS Segment Results €m Q3/2016 Q3/2015 Δ 9M/2016 9M/2015 Δ Sales 203 216 -6% 610 605 1% Sales (adj.)1 204 214 -5% 624 600 4% EBITDA (adj.)2 53 72 -27% 161 181 -11% Margin (adj.)2 25.9% 33.2% 26.4% 30.0% 1) Adjusted for currency and portfolio effects. 2) Adjusted for special items STADA
Slide 7: Branded Products: Q3 Segment Results and Sales by Country
BRANDED PRODUCTS Q3 Segment Results Sales by country Q3/2016 in €m • Germany: Portfolio optimization / strong performance supported by early supply ahead of flu season / Ladival line extensions / Hoggar 43 benefiting from successful marketing activities (+48%) 65 (-7%) Germany • Russia: Challenging
Slide 8: Cashflow Development
CASHFLOW DEVELOPMENT Q3/2016 Q3/2015 Δ 9M/2016 9M/2015 Δ Operating Cashflow 85 97 -13% 198 138 44% Free Cashflow 64 55 16% 79 11 644% (before dividends) Free Cashflow (adj.)1 90 74 22% 133 69 94% (before dividends) 1) Adjusted for significant investments, acquisitions and disposals STADA Analyst Con
Slide 9: Leverage Net Debt/EBITDA (adj.)
LEVERAGE NET DEBT/EBITDA (ADJ.) 4,0 2016 TARGET ~3.0 3,5 3.2 3.2 3.1 3.1 3.1 3.01) 3,0 2.7 2.7 2,5 2,0 2009 2010 2011 2012 2013 2014 2015 Sep 16 1) Linear extrapolation of the adjusted EBITDA of the reporting period on a full year basis STADA Analyst Conference Call 9M • November 10, 2016 Page 9
Slide 10: Well on Track to Reach FY2016 Outlook
WELL ON TRACK TO REACH FY2016 OUTLOOK Sales (adj.1) EBITDA (adj.2) Net income (adj.2) €m 1,522 1,568 3% 294 301 2% 127 140 10% 1-9/2015 1-9/2016 1-9/2015 1-9/2016 1-9/2015 1-9/2016 1) Adjusted for currency and portfolio effects. 2) Adjusted for special items STADA Analyst Conference Call 9M • Novemb
Slide 11: Outlook 2016
OUTLOOK 2016 Before New Sales adj.1 Slight growth EBITDA adj.2 Slight growth Net income adj.2 Slight growth Minimum of € 180m 1) Adjusted for currency and portfolio effects. 2) Adjusted for special items. STADA Analyst Conference Call 9M • November 10, 2016 Page 11
Slide 12: Appendix
APPENDIX STADA Analyst Conference Call 9M • November 10, 2016 Page 12
Slide 13: Reconciliation Q3
RECONCILIATION Q3 Impairments/ Measurement write-ups on Effects from purchase Currency effects of derivative intangible price allocations and CIS/Eastern financial in € million1 Q3/2016 reported assets product acquisitions2 Europe3 instruments Other4 Q3/2016 adjusted EBITDA 88.4 - -0.4 2.2 - 8.1 98.
Slide 14: Reconciliation 9M
RECONCILIATION 9M Impairments/ Measurement write-ups on Effects from purchase Currency effects of derivative intangible price allocations and CIS/Eastern financial in € million1 9M/2016 reported assets product acquisitions2 Europe3 instruments Other4 9M/2016 adjusted EBITDA 289.1 - 0.8 6.6 - 4.1 300
Slide 15: Financial Calendar / Contact
FINANCIAL CALENDAR / CONTACT Financial Calender 2017 March 23, 2017 Publication of FY 2016 results with analyst meeting May 11, 2017 Publication of the Q1 2017 results June 08, 2017 Annual General Meeting 2017 August 03, 2017 Publication of the Q2 2017 results November 09, 2017 Publication of the Q3
Slide 16: Disclaimer and Notes
DISCLAIMER AND NOTES This STADA Arzneimittel AG (hereinafter "STADA") presentation is intended for information only. It is not intended as or provided in connection with an offer or solicitation for the purchase or sale of any security in any jurisdiction. STADA shall not have any liability arising